Simon Shares Insight on Emerging Immunotherapy Regimens in NSCLC – OncLive
OncLive |
Simon Shares Insight on Emerging Immunotherapy Regimens in NSCLC
OncLive In a trial combining immunotherapy with chemotherapy, the phase III KEYNOTE-189 study—the confirmatory trial for the May 2017 FDA approval of pembrolizumab (Keytruda) with carboplatin/pemetrexed—demonstrated improved survival in the frontline … |
